Lung Cancer Palliative Radiotherapy Study Reaches Primary Completion

A Phase 3 clinical trial focused on palliative radiotherapy for Lung Cancer reached its primary completion date on 2025-08-31. The study, which enrolled 1184 participants, aimed to compare different radiotherapy fractionation schemes.

Background

Lung cancer remains a significant global health challenge, often requiring palliative care to manage symptoms and improve quality of life, especially in advanced stages. Palliative radiotherapy is a common intervention used to alleviate symptoms such as pain, cough, and dyspnea. However, treatment regimens can sometimes lead to side effects, including oesophageal toxicity. This study was designed to investigate whether a shorter palliative radiotherapy fractionation scheme could reduce such early toxicities while maintaining or improving patient outcomes.

Trial design

This randomized, multicenter, Phase 3 study, titled "PAlliative RAdioTherapy to Lung Cancer A Randomized Multicentre Phase III Study," enrolled 1184 participants diagnosed with Lung Cancer. The primary objective was to examine if a shorter palliative radiotherapy fractionation scheme of 20 Gy / 4 F could reduce early oesophageal toxicity compared to a standard scheme of 30 Gy / 10 F in patients with lung cancer in performance status (PS) 0-2. Secondary objectives included evaluating the effect on lung cancer symptoms, quality of life (QoL), and survival. The trial also aimed to standardize the quality of palliative thoracic radiotherapy across Danish centers.

What this means

The primary completion of this Phase 3 trial marks a significant milestone in the investigation of optimized palliative radiotherapy for lung cancer. Once results become available, they could provide crucial evidence regarding the efficacy and safety of a shorter fractionation scheme. If the 20 Gy / 4 F regimen proves effective in reducing early oesophageal toxicity without compromising symptom control, quality of life, or survival, it could offer a more patient-friendly and efficient treatment option for individuals with lung cancer requiring palliative care. Such findings could influence clinical guidelines and improve the patient experience.

Source

The information regarding this trial's primary completion was obtained from ClinicalTrials.gov, a public database of clinical studies. The event for study NCT03632603 was reported on 2025-08-31 on clinicaltrials.gov.